AnaptysBio, Inc. (ANAB) 10-Year Financial Performance & Capital Metrics

ANAB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Show more

Revenue $91M +432.0%
EBITDA -$113M +31.3%
Net Income -$145M +11.2%
EPS (Diluted) -5.12 +15.8%
Gross Margin -79.49% +88.2%
EBITDA Margin -123.3% +87.1%
Operating Margin -125.93% +86.9%
Net Margin -159.11% +83.3%
ROE -182.71% -95.5%
ROIC -44.53% +49.4%
Debt/Equity 5.21 +2478.4%
Interest Coverage -2.29 +74.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Strong 5Y sales CAGR of 62.7%

✗Weaknesses

✗High debt to equity ratio of 5.2x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Expensive at 18.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y19.14%

5Y62.73%

3Y13.05%

TTM196.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.91%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.64%

ROCE

10Y Avg-16.85%

5Y Avg-19.18%

3Y Avg-26.29%

Latest-26.94%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.57M	16.68M	10M	5M	8M	75M	63.17M	10.29M	17.16M	91.28M
Revenue Growth %	0.11%	-0.05%	-0.4%	-0.5%	0.6%	8.38%	-0.16%	-0.84%	0.67%	4.32%
Cost of Goods Sold+	17.3M	15.42M	29.44M	56.2M	99.34M	80.03M	98.5M	88.8M	132.28M	163.84M
COGS % of Revenue	0.98%	0.92%	2.94%	11.24%	12.42%	1.07%	1.56%	8.63%	7.71%	1.79%
Gross Profit+	267K	1.26M	-19.44M	-51.2M	-91.34M	-5.03M	-35.32M	-78.51M	-115.13M	-72.56M
Gross Margin %	0.02%	0.08%	-1.94%	-10.24%	-11.42%	-0.07%	-0.56%	-7.63%	-6.71%	-0.79%
Gross Profit Growth %	-0.96%	3.74%	-16.37%	-1.63%	-0.78%	0.94%	-6.03%	-1.22%	-0.47%	0.37%
Operating Expenses+	3.59M	4.29M	9.34M	15.53M	16.09M	18.85M	21.49M	36.64M	49.28M	42.39M
OpEx % of Revenue	0.2%	0.26%	0.93%	3.11%	2.01%	0.25%	0.34%	3.56%	2.87%	0.46%
Selling, General & Admin	3.59M	4.29M	9.34M	15.53M	16.09M	18.85M	21.49M	36.64M	41.95M	42.39M
SG&A % of Revenue	0.2%	0.26%	0.93%	3.11%	2.01%	0.25%	0.34%	3.56%	2.44%	0.46%
Research & Development	17.3M	22.62M	30.94M	56.3M	99.34M	80.03M	98.5M	88.8M	139.62M	163.84M
R&D % of Revenue	0.98%	1.36%	3.09%	11.26%	12.42%	1.07%	1.56%	8.63%	8.14%	1.79%
Other Operating Expenses	-17.3M	-22.62M	-30.94M	-56.3M	-99.34M	-80.03M	-98.5M	-88.8M	-132.28M	-163.84M
Operating Income+	-3.32M	-3.02M	-28.78M	-66.72M	-107.43M	-23.88M	-56.81M	-115.15M	-164.41M	-114.95M
Operating Margin %	-0.19%	-0.18%	-2.88%	-13.34%	-13.43%	-0.32%	-0.9%	-11.19%	-9.58%	-1.26%
Operating Income Growth %	-1.68%	0.09%	-8.51%	-1.32%	-0.61%	0.78%	-1.38%	-1.03%	-0.43%	0.3%
EBITDA+	-3.05M	-2.79M	-28.6M	-66.41M	-106.92M	-23.32M	-54.72M	-112.82M	-163.76M	-112.55M
EBITDA Margin %	-0.17%	-0.17%	-2.86%	-13.28%	-13.36%	-0.31%	-0.87%	-10.97%	-9.54%	-1.23%
EBITDA Growth %	-1.59%	0.08%	-9.24%	-1.32%	-0.61%	0.78%	-1.35%	-1.06%	-0.45%	0.31%
D&A (Non-Cash Add-back)	274K	233K	183K	315K	514K	559K	2.09M	2.33M	652K	2.4M
EBIT	-4.81M	-3.8M	-28.3M	-60.2M	-96.45M	-19.93M	-57.8M	-107.59M	-157.07M	-95.14M
Net Interest Income+	-442K	-331K	-152K	5.03M	9.94M	3.96M	-1.02M	-13.56M	790K	-30.29M
Interest Income	0	0	1.62M	6.68M	10.98M	3.96M	431K	7.55M	18.87M	19.79M
Interest Expense	460K	458K	1.77M	1.65M	1.04M	0	1.45M	21.11M	18.08M	50.09M
Other Income/Expense	-1.94M	-1.23M	-1.29M	4.87M	9.94M	3.95M	-982K	-13.55M	788K	-30.28M
Pretax Income+	-5.27M	-4.26M	-30.07M	-61.85M	-97.49M	-19.93M	-57.8M	-128.7M	-163.62M	-145.23M
Pretax Margin %	-0.3%	-0.26%	-3.01%	-12.37%	-12.19%	-0.27%	-0.91%	-12.51%	-9.54%	-1.59%
Income Tax+	139K	0	0	-192K	-152K	0	0	24K	-4K	3K
Effective Tax Rate %	1.03%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Net Margin %	-0.31%	-0.26%	-3.01%	-12.33%	-12.17%	-0.27%	-0.91%	-12.51%	-9.54%	-1.59%
Net Income Growth %	-24.3%	0.21%	-6.06%	-1.05%	-0.58%	0.8%	-1.9%	-1.23%	-0.27%	0.11%
Net Income (Continuing)	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.23	-1.52	-2.50	-3.60	-0.73	-2.11	-4.57	-6.08	-5.12
EPS Growth %	-2.5%	0.36%	-5.61%	-0.64%	-0.44%	0.8%	-1.89%	-1.17%	-0.33%	0.16%
EPS (Basic)	-0.38	-0.23	-1.52	-2.50	-3.60	-0.73	-2.11	-4.57	-6.08	-5.12
Diluted Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.3M	27.43M	28.16M	26.92M	28.38M
Basic Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.3M	27.43M	28.16M	26.92M	28.38M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.46M	58.21M	252.7M	434.22M	377.73M	396.56M	553.88M	447.2M	406.83M	431.88M
Cash & Short-Term Investments	51.68M	51.23M	248.41M	427.08M	374.23M	393.65M	548.1M	441.24M	390.9M	385.37M
Cash Only	51.68M	51.23M	81.19M	113.6M	171.02M	250.46M	495.73M	71.31M	35.97M	123.08M
Short-Term Investments	0	0	167.22M	313.49M	203.21M	143.2M	52.37M	369.93M	354.94M	262.29M
Accounts Receivable	1.23M	5.34M	1.6M	174K	0	0	876K	1.42M	6.85M	40.77M
Days Sales Outstanding	25.47	116.89	58.44	12.7	-	-	5.06	50.35	145.75	163.01
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	554K	0	0	0	0	0	0	4.54M	9.08M	5.74M
Total Non-Current Assets+	2.82M	3.97M	76.67M	74.78M	57.46M	19.99M	89.19M	163.18M	45.55M	51.96M
Property, Plant & Equipment	551K	471K	665K	1.45M	1.62M	2.13M	21.84M	19.99M	18.27M	16.23M
Fixed Asset Turnover	31.89x	35.42x	15.04x	3.46x	4.94x	35.26x	2.89x	0.51x	0.94x	5.62x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	60K	60K	75.9M	73.13M	54.3M	17.55M	67.1M	142.94M	27.03M	35.47M
Other Non-Current Assets	2.21M	3.44M	106K	208K	1.54M	318K	256K	256K	256K	256K
Total Assets+	56.28M	62.18M	329.36M	509M	435.2M	416.55M	643.07M	610.38M	452.39M	483.83M
Asset Turnover	0.31x	0.27x	0.03x	0.01x	0.02x	0.18x	0.10x	0.02x	0.04x	0.19x
Asset Growth %	1.25%	0.1%	4.3%	0.55%	-0.14%	-0.04%	0.54%	-0.05%	-0.26%	0.07%
Total Current Liabilities+	7.38M	5.71M	14.09M	21.84M	29.54M	19.82M	16.1M	26.05M	37.44M	45.43M
Accounts Payable	1.52M	2.28M	2.32M	5.44M	16.24M	4.22M	1.74M	2.78M	4.7M	4M
Days Payables Outstanding	32.08	53.92	28.8	35.35	59.66	19.23	6.45	11.44	12.96	8.92
Short-Term Debt	0	0	6.88M	7.57M	1.38M	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	772K	973K	1.59M	2.42M	2.15M	3.69M	4.18M	5.38M	23.77M	39.5M
Current Ratio	7.25x	10.20x	17.93x	19.89x	12.79x	20.01x	34.40x	17.16x	10.87x	9.51x
Quick Ratio	7.25x	10.20x	17.93x	19.89x	12.79x	20.01x	34.40x	17.16x	10.87x	9.51x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.57M	17.2M	7.69M	796K	654K	0	270.54M	322.23M	326.84M	367.54M
Long-Term Debt	4.9M	13.81M	7.55M	625K	0	0	0	0	0	353.43M
Capital Lease Obligations	0	0	0	0	654K	0	19.45M	17.81M	16.04M	14.11M
Deferred Tax Liabilities	-115K	-154K	-140K	-171K	0	0	0	0	0	0
Other Non-Current Liabilities	1.66M	3.4M	140K	171K	0	0	251.09M	304.41M	310.81M	0
Total Liabilities	13.94M	22.91M	21.78M	22.63M	30.19M	19.82M	286.64M	348.28M	364.29M	412.97M
Total Debt+	4.92M	13.81M	14.45M	8.26M	2.9M	342K	20.95M	19.45M	17.81M	369.46M
Net Debt	-46.76M	-37.42M	-66.74M	-105.34M	-168.12M	-250.11M	-474.77M	-51.86M	-18.15M	246.38M
Debt / Equity	0.12x	0.35x	0.05x	0.02x	0.01x	0.00x	0.06x	0.07x	0.20x	5.21x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.22x	-6.60x	-16.21x	-40.39x	-103.20x	-	-39.18x	-5.46x	-9.09x	-2.29x
Total Equity+	42.34M	39.27M	307.58M	486.37M	405.01M	396.73M	356.43M	262.1M	88.1M	70.87M
Equity Growth %	6.06%	-0.07%	6.83%	0.58%	-0.17%	-0.02%	-0.1%	-0.26%	-0.66%	-0.2%
Book Value per Share	16.60	14.89	15.55	19.71	14.97	14.53	12.99	9.31	3.27	2.50
Total Shareholders' Equity	42.34M	39.27M	307.58M	486.37M	405.01M	396.73M	356.43M	262.1M	88.1M	70.87M
Common Stock	3K	3K	24K	27K	27K	27K	28K	29K	27K	30K
Retained Earnings	-50.66M	-54.92M	-85.03M	-146.69M	-244.03M	-263.96M	-321.75M	-450.48M	-614.1M	-759.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.58M	-3.8M	-426K	-223K	338K	-4K	-422K	-5.25M	-797K	305K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.67M	-9.03M	-19.44M	-48.51M	-69.52M	-14.16M	-45.92M	-73.59M	-120.8M	-135.34M
Operating CF Margin %	-0.55%	-0.54%	-1.94%	-9.7%	-8.69%	-0.19%	-0.73%	-7.15%	-7.04%	-1.48%
Operating CF Growth %	-1.66%	0.07%	-1.15%	-1.5%	-0.43%	0.8%	-2.24%	-0.6%	-0.64%	-0.12%
Net Income	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Depreciation & Amortization	274K	233K	183K	315K	514K	559K	2.09M	2.33M	2.38M	2.4M
Stock-Based Compensation	604K	1.16M	4.38M	9.96M	0	0	15.35M	27.36M	33.2M	34.05M
Deferred Taxes	1.28M	757K	1.38M	-1.23M	0	0	0	0	0	0
Other Non-Cash Items	110K	105K	619K	646K	10.45M	11.99M	1.93M	18.6M	7.56M	39.77M
Working Capital Changes	-6.53M	-7.03M	4.08M	3.46M	16.85M	-6.77M	-7.49M	6.84M	-324K	-66.33M
Change in Receivables	229K	1K	1.23M	1.43M	174K	0	-876K	-543K	0	-33.91M
Change in Inventory	343K	-5.34M	-237.97M	0	0	0	0	0	0	0
Change in Payables	1.95M	1.25M	2.22M	7.08M	0	0	-4.74M	9.7M	10.94M	-33.84M
Cash from Investing+	-238K	-50K	-243.06M	-142.45M	131.43M	94.47M	38.84M	-394.85M	144.75M	95.4M
Capital Expenditures	-238K	-50K	-290K	-1.06M	-805K	-569K	-1.37M	-358K	-807K	-358K
CapEx % of Revenue	0.01%	0%	0.03%	0.21%	0.1%	0.01%	0.02%	0.03%	0.05%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-290.9M	-347.54M	0	0	15K	-394.49M	0	0
Cash from Financing+	39.4M	8.63M	292.45M	223.36M	-4.49M	-879K	252.3M	44.02M	-59.3M	127.05M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.45M	-1.37M	-84K	2.76M	0	0	249.75M	32.19M	-43K	-8.1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.91M	-9.08M	-19.73M	-49.57M	-70.32M	-14.73M	-47.29M	-73.95M	-121.61M	-135.69M
FCF Margin %	-0.56%	-0.54%	-1.97%	-9.91%	-8.79%	-0.2%	-0.75%	-7.19%	-7.09%	-1.49%
FCF Growth %	-1.69%	0.08%	-1.17%	-1.51%	-0.42%	0.79%	-2.21%	-0.56%	-0.64%	-0.12%
FCF per Share	-3.88	-3.44	-1.00	-2.01	-2.60	-0.54	-1.72	-2.63	-4.52	-4.78
FCF Conversion (FCF/Net Income)	1.79x	2.12x	0.65x	0.79x	0.71x	0.71x	0.79x	0.57x	0.74x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.37%	-10.44%	-17.34%	-15.53%	-21.84%	-4.97%	-15.35%	-41.62%	-93.44%	-182.71%
Return on Invested Capital (ROIC)	-	-	-17.79%	-16.09%	-26.08%	-9.34%	-301.44%	-187.96%	-88.02%	-44.53%
Gross Margin	1.52%	7.58%	-194.43%	-1023.92%	-1141.72%	-6.7%	-55.91%	-763.21%	-671.01%	-79.49%
Net Margin	-30.76%	-25.53%	-300.7%	-1233.12%	-1216.7%	-26.57%	-91.49%	-1251.33%	-953.66%	-159.11%
Debt / Equity	0.12x	0.35x	0.05x	0.02x	0.01x	0.00x	0.06x	0.07x	0.20x	5.21x
Interest Coverage	-7.22x	-6.60x	-16.21x	-40.39x	-103.20x	-	-39.18x	-5.46x	-9.09x	-2.29x
FCF Conversion	1.79x	2.12x	0.65x	0.79x	0.71x	0.71x	0.79x	0.57x	0.74x	0.93x
Revenue Growth	10.94%	-5.05%	-40.06%	-50%	60%	837.5%	-15.77%	-83.72%	66.78%	432.03%

Frequently Asked Questions

Growth & Financials

AnaptysBio, Inc. (ANAB) reported $169.5M in revenue for fiscal year 2024. This represents a 2991% increase from $5.5M in 2013.

AnaptysBio, Inc. (ANAB) grew revenue by 432.0% over the past year. This is strong growth.

AnaptysBio, Inc. (ANAB) reported a net loss of $84.6M for fiscal year 2024.

Dividend & Returns

AnaptysBio, Inc. (ANAB) has a return on equity (ROE) of -182.7%. Negative ROE indicates the company is unprofitable.

AnaptysBio, Inc. (ANAB) had negative free cash flow of $145.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

AnaptysBio, Inc. (ANAB) 10-Year Financial Performance & Capital Metrics

ANAB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $91M +432.0%
EBITDA -$113M +31.3%
Net Income -$145M +11.2%
EPS (Diluted) -5.12 +15.8%
Gross Margin -79.49% +88.2%
EBITDA Margin -123.3% +87.1%
Operating Margin -125.93% +86.9%
Net Margin -159.11% +83.3%
ROE -182.71% -95.5%
ROIC -44.53% +49.4%
Debt/Equity 5.21 +2478.4%
Interest Coverage -2.29 +74.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Strong 5Y sales CAGR of 62.7%

✗Weaknesses

✗High debt to equity ratio of 5.2x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Expensive at 18.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y19.14%

5Y62.73%

3Y13.05%

TTM196.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.91%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.64%

ROCE

10Y Avg-16.85%

5Y Avg-19.18%

3Y Avg-26.29%

Latest-26.94%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.57M	16.68M	10M	5M	8M	75M	63.17M	10.29M	17.16M	91.28M
Revenue Growth %	0.11%	-0.05%	-0.4%	-0.5%	0.6%	8.38%	-0.16%	-0.84%	0.67%	4.32%
Cost of Goods Sold+	17.3M	15.42M	29.44M	56.2M	99.34M	80.03M	98.5M	88.8M	132.28M	163.84M
COGS % of Revenue	0.98%	0.92%	2.94%	11.24%	12.42%	1.07%	1.56%	8.63%	7.71%	1.79%
Gross Profit+	267K	1.26M	-19.44M	-51.2M	-91.34M	-5.03M	-35.32M	-78.51M	-115.13M	-72.56M
Gross Margin %	0.02%	0.08%	-1.94%	-10.24%	-11.42%	-0.07%	-0.56%	-7.63%	-6.71%	-0.79%
Gross Profit Growth %	-0.96%	3.74%	-16.37%	-1.63%	-0.78%	0.94%	-6.03%	-1.22%	-0.47%	0.37%
Operating Expenses+	3.59M	4.29M	9.34M	15.53M	16.09M	18.85M	21.49M	36.64M	49.28M	42.39M
OpEx % of Revenue	0.2%	0.26%	0.93%	3.11%	2.01%	0.25%	0.34%	3.56%	2.87%	0.46%
Selling, General & Admin	3.59M	4.29M	9.34M	15.53M	16.09M	18.85M	21.49M	36.64M	41.95M	42.39M
SG&A % of Revenue	0.2%	0.26%	0.93%	3.11%	2.01%	0.25%	0.34%	3.56%	2.44%	0.46%
Research & Development	17.3M	22.62M	30.94M	56.3M	99.34M	80.03M	98.5M	88.8M	139.62M	163.84M
R&D % of Revenue	0.98%	1.36%	3.09%	11.26%	12.42%	1.07%	1.56%	8.63%	8.14%	1.79%
Other Operating Expenses	-17.3M	-22.62M	-30.94M	-56.3M	-99.34M	-80.03M	-98.5M	-88.8M	-132.28M	-163.84M
Operating Income+	-3.32M	-3.02M	-28.78M	-66.72M	-107.43M	-23.88M	-56.81M	-115.15M	-164.41M	-114.95M
Operating Margin %	-0.19%	-0.18%	-2.88%	-13.34%	-13.43%	-0.32%	-0.9%	-11.19%	-9.58%	-1.26%
Operating Income Growth %	-1.68%	0.09%	-8.51%	-1.32%	-0.61%	0.78%	-1.38%	-1.03%	-0.43%	0.3%
EBITDA+	-3.05M	-2.79M	-28.6M	-66.41M	-106.92M	-23.32M	-54.72M	-112.82M	-163.76M	-112.55M
EBITDA Margin %	-0.17%	-0.17%	-2.86%	-13.28%	-13.36%	-0.31%	-0.87%	-10.97%	-9.54%	-1.23%
EBITDA Growth %	-1.59%	0.08%	-9.24%	-1.32%	-0.61%	0.78%	-1.35%	-1.06%	-0.45%	0.31%
D&A (Non-Cash Add-back)	274K	233K	183K	315K	514K	559K	2.09M	2.33M	652K	2.4M
EBIT	-4.81M	-3.8M	-28.3M	-60.2M	-96.45M	-19.93M	-57.8M	-107.59M	-157.07M	-95.14M
Net Interest Income+	-442K	-331K	-152K	5.03M	9.94M	3.96M	-1.02M	-13.56M	790K	-30.29M
Interest Income	0	0	1.62M	6.68M	10.98M	3.96M	431K	7.55M	18.87M	19.79M
Interest Expense	460K	458K	1.77M	1.65M	1.04M	0	1.45M	21.11M	18.08M	50.09M
Other Income/Expense	-1.94M	-1.23M	-1.29M	4.87M	9.94M	3.95M	-982K	-13.55M	788K	-30.28M
Pretax Income+	-5.27M	-4.26M	-30.07M	-61.85M	-97.49M	-19.93M	-57.8M	-128.7M	-163.62M	-145.23M
Pretax Margin %	-0.3%	-0.26%	-3.01%	-12.37%	-12.19%	-0.27%	-0.91%	-12.51%	-9.54%	-1.59%
Income Tax+	139K	0	0	-192K	-152K	0	0	24K	-4K	3K
Effective Tax Rate %	1.03%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Net Margin %	-0.31%	-0.26%	-3.01%	-12.33%	-12.17%	-0.27%	-0.91%	-12.51%	-9.54%	-1.59%
Net Income Growth %	-24.3%	0.21%	-6.06%	-1.05%	-0.58%	0.8%	-1.9%	-1.23%	-0.27%	0.11%
Net Income (Continuing)	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.23	-1.52	-2.50	-3.60	-0.73	-2.11	-4.57	-6.08	-5.12
EPS Growth %	-2.5%	0.36%	-5.61%	-0.64%	-0.44%	0.8%	-1.89%	-1.17%	-0.33%	0.16%
EPS (Basic)	-0.38	-0.23	-1.52	-2.50	-3.60	-0.73	-2.11	-4.57	-6.08	-5.12
Diluted Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.3M	27.43M	28.16M	26.92M	28.38M
Basic Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.3M	27.43M	28.16M	26.92M	28.38M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.46M	58.21M	252.7M	434.22M	377.73M	396.56M	553.88M	447.2M	406.83M	431.88M
Cash & Short-Term Investments	51.68M	51.23M	248.41M	427.08M	374.23M	393.65M	548.1M	441.24M	390.9M	385.37M
Cash Only	51.68M	51.23M	81.19M	113.6M	171.02M	250.46M	495.73M	71.31M	35.97M	123.08M
Short-Term Investments	0	0	167.22M	313.49M	203.21M	143.2M	52.37M	369.93M	354.94M	262.29M
Accounts Receivable	1.23M	5.34M	1.6M	174K	0	0	876K	1.42M	6.85M	40.77M
Days Sales Outstanding	25.47	116.89	58.44	12.7	-	-	5.06	50.35	145.75	163.01
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	554K	0	0	0	0	0	0	4.54M	9.08M	5.74M
Total Non-Current Assets+	2.82M	3.97M	76.67M	74.78M	57.46M	19.99M	89.19M	163.18M	45.55M	51.96M
Property, Plant & Equipment	551K	471K	665K	1.45M	1.62M	2.13M	21.84M	19.99M	18.27M	16.23M
Fixed Asset Turnover	31.89x	35.42x	15.04x	3.46x	4.94x	35.26x	2.89x	0.51x	0.94x	5.62x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	60K	60K	75.9M	73.13M	54.3M	17.55M	67.1M	142.94M	27.03M	35.47M
Other Non-Current Assets	2.21M	3.44M	106K	208K	1.54M	318K	256K	256K	256K	256K
Total Assets+	56.28M	62.18M	329.36M	509M	435.2M	416.55M	643.07M	610.38M	452.39M	483.83M
Asset Turnover	0.31x	0.27x	0.03x	0.01x	0.02x	0.18x	0.10x	0.02x	0.04x	0.19x
Asset Growth %	1.25%	0.1%	4.3%	0.55%	-0.14%	-0.04%	0.54%	-0.05%	-0.26%	0.07%
Total Current Liabilities+	7.38M	5.71M	14.09M	21.84M	29.54M	19.82M	16.1M	26.05M	37.44M	45.43M
Accounts Payable	1.52M	2.28M	2.32M	5.44M	16.24M	4.22M	1.74M	2.78M	4.7M	4M
Days Payables Outstanding	32.08	53.92	28.8	35.35	59.66	19.23	6.45	11.44	12.96	8.92
Short-Term Debt	0	0	6.88M	7.57M	1.38M	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	772K	973K	1.59M	2.42M	2.15M	3.69M	4.18M	5.38M	23.77M	39.5M
Current Ratio	7.25x	10.20x	17.93x	19.89x	12.79x	20.01x	34.40x	17.16x	10.87x	9.51x
Quick Ratio	7.25x	10.20x	17.93x	19.89x	12.79x	20.01x	34.40x	17.16x	10.87x	9.51x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.57M	17.2M	7.69M	796K	654K	0	270.54M	322.23M	326.84M	367.54M
Long-Term Debt	4.9M	13.81M	7.55M	625K	0	0	0	0	0	353.43M
Capital Lease Obligations	0	0	0	0	654K	0	19.45M	17.81M	16.04M	14.11M
Deferred Tax Liabilities	-115K	-154K	-140K	-171K	0	0	0	0	0	0
Other Non-Current Liabilities	1.66M	3.4M	140K	171K	0	0	251.09M	304.41M	310.81M	0
Total Liabilities	13.94M	22.91M	21.78M	22.63M	30.19M	19.82M	286.64M	348.28M	364.29M	412.97M
Total Debt+	4.92M	13.81M	14.45M	8.26M	2.9M	342K	20.95M	19.45M	17.81M	369.46M
Net Debt	-46.76M	-37.42M	-66.74M	-105.34M	-168.12M	-250.11M	-474.77M	-51.86M	-18.15M	246.38M
Debt / Equity	0.12x	0.35x	0.05x	0.02x	0.01x	0.00x	0.06x	0.07x	0.20x	5.21x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.22x	-6.60x	-16.21x	-40.39x	-103.20x	-	-39.18x	-5.46x	-9.09x	-2.29x
Total Equity+	42.34M	39.27M	307.58M	486.37M	405.01M	396.73M	356.43M	262.1M	88.1M	70.87M
Equity Growth %	6.06%	-0.07%	6.83%	0.58%	-0.17%	-0.02%	-0.1%	-0.26%	-0.66%	-0.2%
Book Value per Share	16.60	14.89	15.55	19.71	14.97	14.53	12.99	9.31	3.27	2.50
Total Shareholders' Equity	42.34M	39.27M	307.58M	486.37M	405.01M	396.73M	356.43M	262.1M	88.1M	70.87M
Common Stock	3K	3K	24K	27K	27K	27K	28K	29K	27K	30K
Retained Earnings	-50.66M	-54.92M	-85.03M	-146.69M	-244.03M	-263.96M	-321.75M	-450.48M	-614.1M	-759.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.58M	-3.8M	-426K	-223K	338K	-4K	-422K	-5.25M	-797K	305K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.67M	-9.03M	-19.44M	-48.51M	-69.52M	-14.16M	-45.92M	-73.59M	-120.8M	-135.34M
Operating CF Margin %	-0.55%	-0.54%	-1.94%	-9.7%	-8.69%	-0.19%	-0.73%	-7.15%	-7.04%	-1.48%
Operating CF Growth %	-1.66%	0.07%	-1.15%	-1.5%	-0.43%	0.8%	-2.24%	-0.6%	-0.64%	-0.12%
Net Income	-5.41M	-4.26M	-30.07M	-61.66M	-97.34M	-19.93M	-57.8M	-128.72M	-163.62M	-145.23M
Depreciation & Amortization	274K	233K	183K	315K	514K	559K	2.09M	2.33M	2.38M	2.4M
Stock-Based Compensation	604K	1.16M	4.38M	9.96M	0	0	15.35M	27.36M	33.2M	34.05M
Deferred Taxes	1.28M	757K	1.38M	-1.23M	0	0	0	0	0	0
Other Non-Cash Items	110K	105K	619K	646K	10.45M	11.99M	1.93M	18.6M	7.56M	39.77M
Working Capital Changes	-6.53M	-7.03M	4.08M	3.46M	16.85M	-6.77M	-7.49M	6.84M	-324K	-66.33M
Change in Receivables	229K	1K	1.23M	1.43M	174K	0	-876K	-543K	0	-33.91M
Change in Inventory	343K	-5.34M	-237.97M	0	0	0	0	0	0	0
Change in Payables	1.95M	1.25M	2.22M	7.08M	0	0	-4.74M	9.7M	10.94M	-33.84M
Cash from Investing+	-238K	-50K	-243.06M	-142.45M	131.43M	94.47M	38.84M	-394.85M	144.75M	95.4M
Capital Expenditures	-238K	-50K	-290K	-1.06M	-805K	-569K	-1.37M	-358K	-807K	-358K
CapEx % of Revenue	0.01%	0%	0.03%	0.21%	0.1%	0.01%	0.02%	0.03%	0.05%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-290.9M	-347.54M	0	0	15K	-394.49M	0	0
Cash from Financing+	39.4M	8.63M	292.45M	223.36M	-4.49M	-879K	252.3M	44.02M	-59.3M	127.05M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.45M	-1.37M	-84K	2.76M	0	0	249.75M	32.19M	-43K	-8.1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.91M	-9.08M	-19.73M	-49.57M	-70.32M	-14.73M	-47.29M	-73.95M	-121.61M	-135.69M
FCF Margin %	-0.56%	-0.54%	-1.97%	-9.91%	-8.79%	-0.2%	-0.75%	-7.19%	-7.09%	-1.49%
FCF Growth %	-1.69%	0.08%	-1.17%	-1.51%	-0.42%	0.79%	-2.21%	-0.56%	-0.64%	-0.12%
FCF per Share	-3.88	-3.44	-1.00	-2.01	-2.60	-0.54	-1.72	-2.63	-4.52	-4.78
FCF Conversion (FCF/Net Income)	1.79x	2.12x	0.65x	0.79x	0.71x	0.71x	0.79x	0.57x	0.74x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.37%	-10.44%	-17.34%	-15.53%	-21.84%	-4.97%	-15.35%	-41.62%	-93.44%	-182.71%
Return on Invested Capital (ROIC)	-	-	-17.79%	-16.09%	-26.08%	-9.34%	-301.44%	-187.96%	-88.02%	-44.53%
Gross Margin	1.52%	7.58%	-194.43%	-1023.92%	-1141.72%	-6.7%	-55.91%	-763.21%	-671.01%	-79.49%
Net Margin	-30.76%	-25.53%	-300.7%	-1233.12%	-1216.7%	-26.57%	-91.49%	-1251.33%	-953.66%	-159.11%
Debt / Equity	0.12x	0.35x	0.05x	0.02x	0.01x	0.00x	0.06x	0.07x	0.20x	5.21x
Interest Coverage	-7.22x	-6.60x	-16.21x	-40.39x	-103.20x	-	-39.18x	-5.46x	-9.09x	-2.29x
FCF Conversion	1.79x	2.12x	0.65x	0.79x	0.71x	0.71x	0.79x	0.57x	0.74x	0.93x
Revenue Growth	10.94%	-5.05%	-40.06%	-50%	60%	837.5%	-15.77%	-83.72%	66.78%	432.03%

Frequently Asked Questions

Growth & Financials

AnaptysBio, Inc. (ANAB) reported $169.5M in revenue for fiscal year 2024. This represents a 2991% increase from $5.5M in 2013.

AnaptysBio, Inc. (ANAB) grew revenue by 432.0% over the past year. This is strong growth.

AnaptysBio, Inc. (ANAB) reported a net loss of $84.6M for fiscal year 2024.

Dividend & Returns

AnaptysBio, Inc. (ANAB) has a return on equity (ROE) of -182.7%. Negative ROE indicates the company is unprofitable.

AnaptysBio, Inc. (ANAB) had negative free cash flow of $145.3M in fiscal year 2024, likely due to heavy capital investments.